Novo Nordisk's Sales Guidance Under Pressure Amidst Competition and Trial Data

Challenges to Novo Nordisk's Sales Guidance

• 📉 Novo Nordisk's consistent history of raising annual sales guidance since the 2021 launch of Wegovy may be nearing an end.
• ⚠️ Recent weak US prescription data has led investors and analysts to question the sustainability of its growth.
• 📊 The company's peak valuation reached $615 billion, but concerns are mounting.

Shifting Growth Projections and Market Dynamics

• 📈 Novo Nordisk forecast 2025 sales growth of 16-24% in February, a slower pace than previous years.
• 📉 Analysts suggest this projection might be too optimistic, with potential for guidance cuts during the first-quarter results on May 7th.
• 💊 While Novo increased Wegovy supplies to meet demand, weekly US prescriptions have plateaued since mid-February.

Competitive Landscape and Future Outlook

• 🥊 Eli Lilly's Zepbound is outpacing Wegovy in recent US prescriptions, intensifying competition.
• ⚠️ The company's products could be affected by potential trade war measures from Donald Trump.
• 📉 Disappointing trial data for its next-generation drug, Kagrasma, and competition concerns have already impacted Novo's market value, wiping off $230 billion since December.
• 💡 Some analysts anticipate a recovery in prescriptions for Wegovy and Amycretin, especially after the FDA enforces a ban on copies in May, potentially allowing Novo to redirect demand.